Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0OFIGC
ADC Name	Anti-PSMA-D265C-30.1699
Synonyms	Anti PSMA D265C 30.1699 Click to Show/Hide
Organization	Heidelberg Pharma Research GmbH
Drug Status	Investigative
Indication	In total 1 Indication(s) Prostate cancer [ICD11:2C82] Investigative
Drug-to-Antibody Ratio	2
	3D MOL	2D MOL
Antibody Name	Anti-PSMA-D265C		Antibody Info
Antigen Name	Glutamate carboxypeptidase 2 (FOLH1)		Antigen Info
Payload Name	Amanitin 30.1699		Payload Info
Therapeutic Target	DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)		Target Info
Linker Name	Mc-Val-Ala-PABC		Linker Info
Conjugate Type	Site-specific conjugation through the engineered cysteine (THIOMAB).

General Information of The Activity Data Related to This ADC

Revealed Based on the Cell Line Data

Click To Hide/Show 2 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Half Maximal Inhibitory Concentration (IC50)	22	pM	LNCaP cells	Prostate carcinoma
Half Maximal Inhibitory Concentration (IC50)	0.11	nM	22RV1 cells	Prostate carcinoma

Full List of Activity Data of This Antibody-drug Conjugate

Revealed Based on the Cell Line Data

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	22.00 pM	Positive PSMA expression (PSMA +++/++)
Method Description	The cytotoxic activity in vitro of ADCs, which are comprising an anti-PSMA antibody carrying a D265C mutation conjugated tostructurally different amanitin derivatives via its D265C residue was tested on LNCaP cells and 22RV1 cells.
In Vitro Model	Prostate carcinoma	LNCaP cells		CVCL_0395
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.11 nM	Positive PSMA expression (PSMA +++/++)
Method Description	The cytotoxic activity in vitro of ADCs, which are comprising an anti-PSMA antibody carrying a D265C mutation conjugated tostructurally different amanitin derivatives via its D265C residue was tested on LNCaP cells and 22RV1 cells.
In Vitro Model	Prostate carcinoma	22RV1 cells		CVCL_1045

References

Ref 1	Amatoxin antibody-drug conjugates and uses thereof; 2020-10-29.